Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

IMPORTANCE: Tumor mutational burden (TMB), as measured by whole-exome sequencing (WES) or a cancer gene panel (CGP), is associated with immunotherapy responses. However, whether TMB estimated by circulating tumor DNA in blood (bTMB) is associated with clinical outcomes of immunotherapy remains to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhijie, Duan, Jianchun, Cai, Shangli, Han, Miao, Dong, Hua, Zhao, Jun, Zhu, Bo, Wang, Shuhang, Zhuo, Minglei, Sun, Jianguo, Wang, Qiming, Bai, Hua, Han, Jiefei, Tian, Yanhua, Lu, Jing, Xu, Tongfu, Zhao, Xiaochen, Wang, Guoqiang, Cao, Xinkai, Li, Fugen, Wang, Dalei, Chen, Yuejun, Bai, Yuezong, Zhao, Jing, Zhao, Zhengyi, Zhang, Yuzi, Xiong, Lei, He, Jie, Gao, Shugeng, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512308/
https://www.ncbi.nlm.nih.gov/pubmed/30816954
http://dx.doi.org/10.1001/jamaoncol.2018.7098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512308/
https://www.ncbi.nlm.nih.gov/pubmed/30816954
http://dx.doi.org/10.1001/jamaoncol.2018.7098

Ejemplares similares